Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Robert W. Baird & Co. to hold a virtual conference » 04:55
09/15/21
09/15
04:55
09/15/21
04:55
ABUS

Arbutus Biopharma

$4.25 /

-0.005 (-0.12%)

, AHCO

AdaptHealth

$23.85 /

-0.04 (-0.17%)

, ASMB

Assembly Biosciences

$3.26 /

-0.055 (-1.66%)

, FATE

Fate Therapeutics

$64.86 /

-0.95 (-1.44%)

, STE

Steris

$215.95 /

+5.59 (+2.66%)

, IQV

Iqvia

$257.63 /

+2.01 (+0.79%)

, IVC

Invacare

$5.91 /

-0.62 (-9.49%)

, ICPT

Intercept

$15.15 /

+0.365 (+2.47%)

, HGEN

Humanigen

$6.09 /

-0.155 (-2.48%)

, GERN

Geron

$1.33 /

-0.06 (-4.33%)

, NTRA

Natera

$120.16 /

-0.07 (-0.06%)

, JNCE

Jounce Therapeutics

$7.26 /

+0.785 (+12.12%)

, COO

Cooper Companies

$441.45 /

+0.87 (+0.20%)

, NOVT

Novanta

$150.22 /

-2.125 (-1.39%)

, MYOV

Myovant Sciences

$21.50 /

-1.28 (-5.62%)

, SRPT

Sarepta

$80.18 /

-1.68 (-2.05%)

, RCM

R1 RCM

$20.24 /

-0.17 (-0.83%)

, XRAY

Dentsply Sirona

$61.79 /

-0.05 (-0.08%)

, VIR

Vir Biotechnology

$50.17 /

+0.17 (+0.34%)

, TNDM

TNDM

/

+

, TLMD

SOC Telemed

$2.84 /

-0.07 (-2.41%)

, TRHC

Tabula Rasa HealthCare

$28.82 /

-0.92 (-3.09%)

, ZBH

Zimmer Biomet

$147.63 /

+6.69 (+4.75%)

, MRVL

Marvell

$62.30 /

-0.09 (-0.14%)

, TIL

Instil Bio

$16.45 /

-1.28 (-7.22%)

, TECH

Bio-Techne

$510.50 /

+8.11 (+1.61%)

, TALK

Talkspace

$4.71 /

-0.145 (-2.99%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference 2021 to be held on September 14-15.

ShowHide Related Items >><<
ZBH Zimmer Biomet
$147.63 /

+6.69 (+4.75%)

XRAY Dentsply Sirona
$61.79 /

-0.05 (-0.08%)

VIR Vir Biotechnology
$50.17 /

+0.17 (+0.34%)

TRHC Tabula Rasa HealthCare
$28.82 /

-0.92 (-3.09%)

TNDM TNDM
/

+

TLMD SOC Telemed
$2.84 /

-0.07 (-2.41%)

TIL Instil Bio
$16.45 /

-1.28 (-7.22%)

TECH Bio-Techne
$510.50 /

+8.11 (+1.61%)

TALK Talkspace
$4.71 /

-0.145 (-2.99%)

STE Steris
$215.95 /

+5.59 (+2.66%)

SRPT Sarepta
$80.18 /

-1.68 (-2.05%)

RCM R1 RCM
$20.24 /

-0.17 (-0.83%)

NTRA Natera
$120.16 /

-0.07 (-0.06%)

NOVT Novanta
$150.22 /

-2.125 (-1.39%)

MYOV Myovant Sciences
$21.50 /

-1.28 (-5.62%)

MRVL Marvell
$62.30 /

-0.09 (-0.14%)

JNCE Jounce Therapeutics
$7.26 /

+0.785 (+12.12%)

IVC Invacare
$5.91 /

-0.62 (-9.49%)

IQV Iqvia
$257.63 /

+2.01 (+0.79%)

ICPT Intercept
$15.15 /

+0.365 (+2.47%)

HGEN Humanigen
$6.09 /

-0.155 (-2.48%)

GERN Geron
$1.33 /

-0.06 (-4.33%)

FATE Fate Therapeutics
$64.86 /

-0.95 (-1.44%)

COO Cooper Companies
$441.45 /

+0.87 (+0.20%)

ASMB Assembly Biosciences
$3.26 /

-0.055 (-1.66%)

AHCO AdaptHealth
$23.85 /

-0.04 (-0.17%)

ABUS Arbutus Biopharma
$4.25 /

-0.005 (-0.12%)

ABUS Arbutus Biopharma
$4.25 /

-0.005 (-0.12%)

06/28/21 JMP Securities
Arbutus EASL updates still support progress in Chronic HBV, says JMP Securities
03/10/21 B. Riley
Arbutus Biopharma price target lowered to $7 from $8 at B. Riley Securities
12/17/20 H.C. Wainwright
Arbutus Biopharma initiated with a Buy at H.C. Wainwright
09/15/20 Chardan
Arbutus HBV data 'could represent a turning point,' says Chardan
AHCO AdaptHealth
$23.85 /

-0.04 (-0.17%)

07/14/21 Baird
AdaptHealth upgraded to Outperform on increasing investor confidence at Baird
07/14/21 Baird
AdaptHealth upgraded to Outperform from Neutral at Baird
07/08/21 Jefferies
Medicare home oxygen proposal positive for AdaptHealth, says Jefferies
05/07/21 Canaccord
AdaptHealth price target lowered to $44 from $50 at Canaccord
ASMB Assembly Biosciences
$3.26 /

-0.055 (-1.66%)

09/13/21 H.C. Wainwright
Assembly Biosciences initiated with a Neutral at H.C. Wainwright
09/03/21 Mizuho
Assembly stopping H2158 development not necessarily bad thing, says Mizuho
09/02/21
Fly Intel: Top five analyst downgrades
09/02/21 William Blair
William Blair downgrades Assembly Biosciences on H2158 discontinuation
FATE Fate Therapeutics
$64.86 /

-0.95 (-1.44%)

08/26/21
Fly Intel: Top five analyst initiations
08/26/21 Morgan Stanley
Fate Therapeutics initiated with an Equal Weight at Morgan Stanley
08/26/21 Morgan Stanley
Fate Therapeutics initiated with an Equal Weight at Morgan Stanley
08/20/21 Piper Sandler
Fate Therapeutics selloff on data a buying opportunity, says Piper Sandler
STE Steris
$215.95 /

+5.59 (+2.66%)

08/11/21 KeyBanc
Steris price target raised to $239 from $227 at KeyBanc
08/11/21 Stephens
Steris price target raised to $255 from $217 at Stephens
08/11/21 Baird
Steris price target raised to $250 from $230 at Baird
05/26/21
Fly Intel: Top five analyst upgrades
IQV Iqvia
$257.63 /

+2.01 (+0.79%)

09/10/21 Argus
Iqvia price target raised to $290 from $260 at Argus
08/04/21 Credit Suisse
Iqvia assumed with an Outperform at Credit Suisse
07/28/21 Piper Sandler
Iqvia price target raised to $235 from $204 at Piper Sandler
07/28/21 Deutsche Bank
Iqvia price target raised to $250 from $244 at Deutsche Bank
IVC Invacare
$5.91 /

-0.62 (-9.49%)

09/10/21 Needham
Invacare price target lowered to $8 from $17 at Needham
08/19/21 Oppenheimer
Invacare initiated with an Outperform at Oppenheimer
ICPT Intercept
$15.15 /

+0.365 (+2.47%)

08/20/21
Fly Intel: Top five analyst downgrades
08/20/21 Goldman Sachs
Intercept downgraded to Sell from Neutral at Goldman Sachs
08/03/21 B. Riley
Intercept price target raised to $22 from $18 at B. Riley
08/02/21 Wedbush
Intercept price target lowered to $67 from $74 at Wedbush
HGEN Humanigen
$6.09 /

-0.155 (-2.48%)

09/10/21
Fly Intel: Top five analyst downgrades
09/10/21 Jefferies
Humanigen downgraded to Hold from Buy at Jefferies
09/09/21 Credit Suisse
Credit Suisse cuts Humanigen to Neutral after FDA denies lenzilumab EUA
09/09/21 Credit Suisse
Humanigen downgraded to Neutral from Outperform at Credit Suisse
GERN Geron
$1.33 /

-0.06 (-4.33%)

02/18/21 B. Riley
Geron transferred with Buy rating at B. Riley Securities
10/14/20 B. Riley
Geron shares have 100% potential upside, says B. Riley Securities
NTRA Natera
$120.16 /

-0.07 (-0.06%)

08/31/21 Craig-Hallum
Natera seeks to challenge CareDx franchise with launch, says Craig-Hallum
08/09/21 Piper Sandler
Natera price target raised to $160 from $155 at Piper Sandler
08/06/21 Wells Fargo
Natera price target raised to $135 from $125 at Wells Fargo
08/06/21 Baird
Natera price target raised to $145 from $127 at Baird
JNCE Jounce Therapeutics
$7.26 /

+0.785 (+12.12%)

09/14/21 Raymond James
Jounce Therapeutics upgraded to Outperform with $10 target at Raymond James
09/14/21 Raymond James
Jounce Therapeutics upgraded to Outperform from Market Perform at Raymond James
08/05/21 Piper Sandler
Jounce Therapeutics price target lowered to $17 from $20 at Piper Sandler
06/16/21 Roth Capital
JTX-1811 IND-clearance further validates Jounce platform, says Roth Capital
COO Cooper Companies
$441.45 /

+0.87 (+0.20%)

09/03/21 Stifel
Cooper Companies price target raised to $475 from $450 at Stifel
09/03/21 Citi
Cooper Companies price target raised to $453 from $400 at Citi
09/03/21 Oppenheimer
Cooper Companies price target raised to $475 from $405 at Oppenheimer
09/03/21 KeyBanc
Cooper Companies price target raised to $476 from $444 at KeyBanc
NOVT Novanta
$150.22 /

-2.125 (-1.39%)

11/13/20 Berenberg
Novanta initiated with a Hold at Berenberg
MYOV Myovant Sciences
$21.50 /

-1.28 (-5.62%)

09/09/21 SVB Leerink
SVB Leerink starts Myovant at Market Perform
09/09/21 SVB Leerink
Myovant Sciences initiated with a Market Perform at SVB Leerink
08/19/21 Goldman Sachs
Myovant Sciences assumed with a Neutral at Goldman Sachs
05/13/21 Citi
Myovant Sciences price target lowered to $24 from $30 at Citi
SRPT Sarepta
$80.18 /

-1.68 (-2.05%)

08/05/21 JPMorgan
Sarepta upgraded to Neutral after 60% selloff at JPMorgan
08/05/21 JPMorgan
Sarepta upgraded to Neutral from Underweight at JPMorgan
07/01/21 Berenberg
Sarepta assumed with a Hold at Berenberg
06/14/21 BTIG
Sarepta initiated with a Buy at BTIG
RCM R1 RCM
$20.24 /

-0.17 (-0.83%)

07/22/21
Fly Intel: Top five analyst initiations
07/22/21 BofA
BofA starts R1 RCM at Buy, sees 32% upside potential
07/22/21 BofA
R1 RCM initiated with a Buy at BofA
06/02/21 Baird
R1 RCM initiated with an Outperform at Baird
XRAY Dentsply Sirona
$61.79 /

-0.05 (-0.08%)

08/10/21 Goldman Sachs
SmileDirectClub price target lowered to $4 from $7 at Goldman Sachs
08/09/21 H.C. Wainwright
Dentsply Sirona price target lowered to $66 from $72 at H.C. Wainwright
08/06/21 Barrington
Dentsply Sirona price target raised to $79 from $77 at Barrington
08/06/21 Piper Sandler
Dentsply Sirona weakness a buying opportunity, says Piper Sandler
VIR Vir Biotechnology
$50.17 /

+0.17 (+0.34%)

06/03/21 Baird
Vir Biotechnology assumed with a Neutral at Baird
05/27/21 Piper Sandler
Xencorc royalty revenue streams growing, says Piper Sandler
03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
03/08/21 H.C. Wainwright
Vir Biotechnology price target raised to $135 from $125 at H.C. Wainwright
TNDM TNDM
/

+

08/05/21 SVB Leerink
Tandem Diabetes price target raised to $123 from $102 at SVB Leerink
08/05/21 Craig-Hallum
Tandem Diabetes price target raised to $153 from $140 at Craig-Hallum
08/05/21 Wells Fargo
Tandem Diabetes price target raised to $121 from $112 at Wells Fargo
08/05/21 Oppenheimer
Tandem Diabetes price target raised to $140 from $135 at Oppenheimer
TLMD SOC Telemed
$2.84 /

-0.07 (-2.41%)

09/01/21 Benchmark
SOC Telemed CEO change due to 'uneven' performance, says Benchmark
08/13/21 RBC Capital
SOC Telemed price target lowered to $6 from $10 at RBC Capital
08/13/21 Benchmark
SOC Telemed price target lowered to $7 from $10 at Benchmark
05/28/21 Baird
Baird starts 'uniquely well-positioned' SOC Telemed with an Outperform
TRHC Tabula Rasa HealthCare
$28.82 /

-0.92 (-3.09%)

06/03/21 Truist
Tabula Rasa HealthCare price target raised to $47 from $42 at Truist
05/28/21 Baird
Baird starts Tabula Rasa HealthCare with Outperform amid low expectations
05/27/21 Baird
Tabula Rasa HealthCare initiated with an Outperform at Baird
05/07/21 Piper Sandler
Tabula Rasa price target raised to $45 from $41 at Piper Sandler
ZBH Zimmer Biomet
$147.63 /

+6.69 (+4.75%)

09/14/21 Raymond James
Zimmer Biomet resumed with a Market Perform at Raymond James
08/30/21 Cowen
Zimmer Biomet approval 'kicks off' smart implant era in orthopedics, says Cowen
08/30/21 Piper Sandler
Piper says Persona IQ represents 'another exciting approval' for Zimmer Biomet
08/25/21 Citi
Citi adds Medtronic to Focus List, boosts price target
MRVL Marvell
$62.30 /

-0.09 (-0.14%)

08/27/21
Fly Intel: Top five analyst downgrades
08/27/21 Craig-Hallum
Marvell downgraded to Hold on valuation at Craig-Hallum
08/27/21 Craig-Hallum
Marvell downgraded to Hold from Buy at Craig-Hallum
08/27/21 B. Riley
Marvell earnings selloff brings 'enhanced entry point,' says B. Riley
TIL Instil Bio
$16.45 /

-1.28 (-7.22%)

08/13/21 Baird
Baird sees likely success for Instil Bio lead candidate, starts at Outperform
08/12/21 Baird
Instil Bio initiated with an Outperform at Baird
06/29/21 Chardan
Iovance data show activity but 'not a home run,' says Chardan
05/19/21 Chardan
Iovance Biotherapeutics price target lowered to $51 from $54 at Chardan
TECH Bio-Techne
$510.50 /

+8.11 (+1.61%)

09/15/21 KeyBanc
Bio-Techne upgraded to Overweight from Sector Weight at KeyBanc
08/24/21 Argus
Bio-Techne price target raised to $540 from $490 at Argus
08/06/21 Baird
Bio-Techne price target raised to $522 from $430 at Baird
08/05/21 Benchmark
Bio-Techne price target raised to $540 from $480 at Benchmark
TALK Talkspace
$4.71 /

-0.145 (-2.99%)

08/19/21 Citi
Talkspace initiated with a Buy at Citi
07/19/21 William Blair
Talkspace initiated with an Outperform at William Blair
07/08/21 Baird
Talkspace initiated with an Outperform at Baird
07/06/21 Cowen
Talkspace initiated with an Outperform at Cowen
ZBH Zimmer Biomet
$147.63 /

+6.69 (+4.75%)

XRAY Dentsply Sirona
$61.79 /

-0.05 (-0.08%)

VIR Vir Biotechnology
$50.17 /

+0.17 (+0.34%)

TRHC Tabula Rasa HealthCare
$28.82 /

-0.92 (-3.09%)

TNDM TNDM
/

+

TLMD SOC Telemed
$2.84 /

-0.07 (-2.41%)

TIL Instil Bio
$16.45 /

-1.28 (-7.22%)

TALK Talkspace
$4.71 /

-0.145 (-2.99%)

STE Steris
$215.95 /

+5.59 (+2.66%)

SRPT Sarepta
$80.18 /

-1.68 (-2.05%)

RCM R1 RCM
$20.24 /

-0.17 (-0.83%)

NTRA Natera
$120.16 /

-0.07 (-0.06%)

NOVT Novanta
$150.22 /

-2.125 (-1.39%)

MYOV Myovant Sciences
$21.50 /

-1.28 (-5.62%)

MRVL Marvell
$62.30 /

-0.09 (-0.14%)

JNCE Jounce Therapeutics
$7.26 /

+0.785 (+12.12%)

IVC Invacare
$5.91 /

-0.62 (-9.49%)

IQV Iqvia
$257.63 /

+2.01 (+0.79%)

ICPT Intercept
$15.15 /

+0.365 (+2.47%)

HGEN Humanigen
$6.09 /

-0.155 (-2.48%)

GERN Geron
$1.33 /

-0.06 (-4.33%)

FATE Fate Therapeutics
$64.86 /

-0.95 (-1.44%)

COO Cooper Companies
$441.45 /

+0.87 (+0.20%)

ASMB Assembly Biosciences
$3.26 /

-0.055 (-1.66%)

AHCO AdaptHealth
$23.85 /

-0.04 (-0.17%)

ABUS Arbutus Biopharma
$4.25 /

-0.005 (-0.12%)

  • 22
    Jul
  • 27
    May
  • 27
    May
  • 31
    Mar
  • 19
    Mar
  • 10
    Mar
  • 06
    Jan
  • 06
    Jan
  • 15
    Dec
  • 18
    Sep
XRAY Dentsply Sirona
$61.79 /

-0.05 (-0.08%)

SRPT Sarepta
$80.18 /

-1.68 (-2.05%)

MRVL Marvell
$62.30 /

-0.09 (-0.14%)

ZBH Zimmer Biomet
$147.63 /

+6.69 (+4.75%)

VIR Vir Biotechnology
$50.17 /

+0.17 (+0.34%)

TLMD SOC Telemed
$2.84 /

-0.07 (-2.41%)

TIL Instil Bio
$16.45 /

-1.28 (-7.22%)

STE Steris
$215.95 /

+5.59 (+2.66%)

SRPT Sarepta
$80.18 /

-1.68 (-2.05%)

RCM R1 RCM
$20.24 /

-0.17 (-0.83%)

NTRA Natera
$120.16 /

-0.07 (-0.06%)

MYOV Myovant Sciences
$21.50 /

-1.28 (-5.62%)

MRVL Marvell
$62.30 /

-0.09 (-0.14%)

IVC Invacare
$5.91 /

-0.62 (-9.49%)

ICPT Intercept
$15.15 /

+0.365 (+2.47%)

HGEN Humanigen
$6.09 /

-0.155 (-2.48%)

GERN Geron
$1.33 /

-0.06 (-4.33%)

FATE Fate Therapeutics
$64.86 /

-0.95 (-1.44%)

AHCO AdaptHealth
$23.85 /

-0.04 (-0.17%)

ABUS Arbutus Biopharma
$4.25 /

-0.005 (-0.12%)

TALK Talkspace
$4.71 /

-0.145 (-2.99%)

STE Steris
$215.95 /

+5.59 (+2.66%)

MRVL Marvell
$62.30 /

-0.09 (-0.14%)

HGEN Humanigen
$6.09 /

-0.155 (-2.48%)

GERN Geron
$1.33 /

-0.06 (-4.33%)

COO Cooper Companies
$441.45 /

+0.87 (+0.20%)

ABUS Arbutus Biopharma
$4.25 /

-0.005 (-0.12%)

Tuesday
Conference/Events
Robert W. Baird & Co. to hold a virtual conference » 10:00
09/14/21
09/14
10:00
09/14/21
10:00
ABUS

Arbutus Biopharma

$4.22 /

-0.035 (-0.82%)

, AHCO

AdaptHealth

$24.25 /

+0.36 (+1.51%)

, ASMB

Assembly Biosciences

$3.30 /

-0.01 (-0.30%)

, FATE

Fate Therapeutics

$66.74 /

+0.93 (+1.41%)

, STE

Steris

$211.52 /

+1.16 (+0.55%)

, IQV

Iqvia

$258.35 /

+2.73 (+1.07%)

, IVC

Invacare

$6.95 /

+0.42 (+6.43%)

, ICPT

Intercept

$14.66 /

-0.125 (-0.85%)

, HGEN

Humanigen

$6.35 /

+0.11 (+1.76%)

, GERN

Geron

$1.38 /

-0.01 (-0.72%)

, NTRA

Natera

$122.38 /

+2.15 (+1.79%)

, JNCE

Jounce Therapeutics

$7.23 /

+0.755 (+11.66%)

, COO

Cooper Companies

$442.66 /

+2.08 (+0.47%)

, NOVT

Novanta

$151.80 /

-0.545 (-0.36%)

, MYOV

Myovant Sciences

$22.85 /

+0.07 (+0.31%)

, SRPT

Sarepta

$81.79 /

-0.07 (-0.09%)

, RCM

R1 RCM

$20.47 /

+0.06 (+0.29%)

, XRAY

Dentsply Sirona

$62.66 /

+0.82 (+1.33%)

, VIR

Vir Biotechnology

$51.51 /

+1.51 (+3.02%)

, TNDM

TNDM

/

+

, TLMD

SOC Telemed

$2.97 /

+0.065 (+2.24%)

, TRHC

Tabula Rasa HealthCare

$29.76 /

+0.02 (+0.07%)

, ZBH

Zimmer Biomet

$140.76 /

-0.18 (-0.13%)

, MRVL

Marvell

$62.64 /

+0.25 (+0.40%)

, TIL

Instil Bio

$18.57 /

+0.84 (+4.74%)

, TECH

Bio-Techne

$510.21 /

+7.82 (+1.56%)

, TALK

Talkspace

$4.84 /

-0.015 (-0.31%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference 2021 to be held on September 14-15.

ShowHide Related Items >><<
ZBH Zimmer Biomet
$140.76 /

-0.18 (-0.13%)

XRAY Dentsply Sirona
$62.66 /

+0.82 (+1.33%)

VIR Vir Biotechnology
$51.51 /

+1.51 (+3.02%)

TRHC Tabula Rasa HealthCare
$29.76 /

+0.02 (+0.07%)

TNDM TNDM
/

+

TLMD SOC Telemed
$2.97 /

+0.065 (+2.24%)

TIL Instil Bio
$18.57 /

+0.84 (+4.74%)

TECH Bio-Techne
$510.21 /

+7.82 (+1.56%)

TALK Talkspace
$4.84 /

-0.015 (-0.31%)

STE Steris
$211.52 /

+1.16 (+0.55%)

SRPT Sarepta
$81.79 /

-0.07 (-0.09%)

RCM R1 RCM
$20.47 /

+0.06 (+0.29%)

NTRA Natera
$122.38 /

+2.15 (+1.79%)

NOVT Novanta
$151.80 /

-0.545 (-0.36%)

MYOV Myovant Sciences
$22.85 /

+0.07 (+0.31%)

MRVL Marvell
$62.64 /

+0.25 (+0.40%)

JNCE Jounce Therapeutics
$7.23 /

+0.755 (+11.66%)

IVC Invacare
$6.95 /

+0.42 (+6.43%)

IQV Iqvia
$258.35 /

+2.73 (+1.07%)

ICPT Intercept
$14.66 /

-0.125 (-0.85%)

HGEN Humanigen
$6.35 /

+0.11 (+1.76%)

GERN Geron
$1.38 /

-0.01 (-0.72%)

FATE Fate Therapeutics
$66.74 /

+0.93 (+1.41%)

COO Cooper Companies
$442.66 /

+2.08 (+0.47%)

ASMB Assembly Biosciences
$3.30 /

-0.01 (-0.30%)

AHCO AdaptHealth
$24.25 /

+0.36 (+1.51%)

ABUS Arbutus Biopharma
$4.22 /

-0.035 (-0.82%)

ABUS Arbutus Biopharma
$4.22 /

-0.035 (-0.82%)

06/28/21 JMP Securities
Arbutus EASL updates still support progress in Chronic HBV, says JMP Securities
03/10/21 B. Riley
Arbutus Biopharma price target lowered to $7 from $8 at B. Riley Securities
12/17/20 H.C. Wainwright
Arbutus Biopharma initiated with a Buy at H.C. Wainwright
09/15/20 Chardan
Arbutus HBV data 'could represent a turning point,' says Chardan
AHCO AdaptHealth
$24.25 /

+0.36 (+1.51%)

07/14/21 Baird
AdaptHealth upgraded to Outperform on increasing investor confidence at Baird
07/14/21 Baird
AdaptHealth upgraded to Outperform from Neutral at Baird
07/08/21 Jefferies
Medicare home oxygen proposal positive for AdaptHealth, says Jefferies
05/07/21 Canaccord
AdaptHealth price target lowered to $44 from $50 at Canaccord
ASMB Assembly Biosciences
$3.30 /

-0.01 (-0.30%)

09/13/21 H.C. Wainwright
Assembly Biosciences initiated with a Neutral at H.C. Wainwright
09/03/21 Mizuho
Assembly stopping H2158 development not necessarily bad thing, says Mizuho
09/02/21
Fly Intel: Top five analyst downgrades
09/02/21 William Blair
William Blair downgrades Assembly Biosciences on H2158 discontinuation
FATE Fate Therapeutics
$66.74 /

+0.93 (+1.41%)

08/26/21
Fly Intel: Top five analyst initiations
08/26/21 Morgan Stanley
Fate Therapeutics initiated with an Equal Weight at Morgan Stanley
08/26/21 Morgan Stanley
Fate Therapeutics initiated with an Equal Weight at Morgan Stanley
08/20/21 Piper Sandler
Fate Therapeutics selloff on data a buying opportunity, says Piper Sandler
STE Steris
$211.52 /

+1.16 (+0.55%)

08/11/21 KeyBanc
Steris price target raised to $239 from $227 at KeyBanc
08/11/21 Stephens
Steris price target raised to $255 from $217 at Stephens
08/11/21 Baird
Steris price target raised to $250 from $230 at Baird
05/26/21
Fly Intel: Top five analyst upgrades
IQV Iqvia
$258.35 /

+2.73 (+1.07%)

09/10/21 Argus
Iqvia price target raised to $290 from $260 at Argus
08/04/21 Credit Suisse
Iqvia assumed with an Outperform at Credit Suisse
07/28/21 Piper Sandler
Iqvia price target raised to $235 from $204 at Piper Sandler
07/28/21 Deutsche Bank
Iqvia price target raised to $250 from $244 at Deutsche Bank
IVC Invacare
$6.95 /

+0.42 (+6.43%)

09/10/21 Needham
Invacare price target lowered to $8 from $17 at Needham
08/19/21 Oppenheimer
Invacare initiated with an Outperform at Oppenheimer
ICPT Intercept
$14.66 /

-0.125 (-0.85%)

08/20/21
Fly Intel: Top five analyst downgrades
08/20/21 Goldman Sachs
Intercept downgraded to Sell from Neutral at Goldman Sachs
08/03/21 B. Riley
Intercept price target raised to $22 from $18 at B. Riley
08/02/21 Wedbush
Intercept price target lowered to $67 from $74 at Wedbush
HGEN Humanigen
$6.35 /

+0.11 (+1.76%)

09/10/21
Fly Intel: Top five analyst downgrades
09/10/21 Jefferies
Humanigen downgraded to Hold from Buy at Jefferies
09/09/21 Credit Suisse
Credit Suisse cuts Humanigen to Neutral after FDA denies lenzilumab EUA
09/09/21 Credit Suisse
Humanigen downgraded to Neutral from Outperform at Credit Suisse
GERN Geron
$1.38 /

-0.01 (-0.72%)

02/18/21 B. Riley
Geron transferred with Buy rating at B. Riley Securities
10/14/20 B. Riley
Geron shares have 100% potential upside, says B. Riley Securities
NTRA Natera
$122.38 /

+2.15 (+1.79%)

08/31/21 Craig-Hallum
Natera seeks to challenge CareDx franchise with launch, says Craig-Hallum
08/09/21 Piper Sandler
Natera price target raised to $160 from $155 at Piper Sandler
08/06/21 Wells Fargo
Natera price target raised to $135 from $125 at Wells Fargo
08/06/21 Baird
Natera price target raised to $145 from $127 at Baird
JNCE Jounce Therapeutics
$7.23 /

+0.755 (+11.66%)

09/14/21 Raymond James
Jounce Therapeutics upgraded to Outperform with $10 target at Raymond James
09/14/21 Raymond James
Jounce Therapeutics upgraded to Outperform from Market Perform at Raymond James
08/05/21 Piper Sandler
Jounce Therapeutics price target lowered to $17 from $20 at Piper Sandler
06/16/21 Roth Capital
JTX-1811 IND-clearance further validates Jounce platform, says Roth Capital
COO Cooper Companies
$442.66 /

+2.08 (+0.47%)

09/03/21 Stifel
Cooper Companies price target raised to $475 from $450 at Stifel
09/03/21 Citi
Cooper Companies price target raised to $453 from $400 at Citi
09/03/21 Oppenheimer
Cooper Companies price target raised to $475 from $405 at Oppenheimer
09/03/21 KeyBanc
Cooper Companies price target raised to $476 from $444 at KeyBanc
NOVT Novanta
$151.80 /

-0.545 (-0.36%)

11/13/20 Berenberg
Novanta initiated with a Hold at Berenberg
MYOV Myovant Sciences
$22.85 /

+0.07 (+0.31%)

09/09/21 SVB Leerink
SVB Leerink starts Myovant at Market Perform
09/09/21 SVB Leerink
Myovant Sciences initiated with a Market Perform at SVB Leerink
08/19/21 Goldman Sachs
Myovant Sciences assumed with a Neutral at Goldman Sachs
05/13/21 Citi
Myovant Sciences price target lowered to $24 from $30 at Citi
SRPT Sarepta
$81.79 /

-0.07 (-0.09%)

08/05/21 JPMorgan
Sarepta upgraded to Neutral after 60% selloff at JPMorgan
08/05/21 JPMorgan
Sarepta upgraded to Neutral from Underweight at JPMorgan
07/01/21 Berenberg
Sarepta assumed with a Hold at Berenberg
06/14/21 BTIG
Sarepta initiated with a Buy at BTIG
RCM R1 RCM
$20.47 /

+0.06 (+0.29%)

07/22/21
Fly Intel: Top five analyst initiations
07/22/21 BofA
BofA starts R1 RCM at Buy, sees 32% upside potential
07/22/21 BofA
R1 RCM initiated with a Buy at BofA
06/02/21 Baird
R1 RCM initiated with an Outperform at Baird
XRAY Dentsply Sirona
$62.66 /

+0.82 (+1.33%)

08/10/21 Goldman Sachs
SmileDirectClub price target lowered to $4 from $7 at Goldman Sachs
08/09/21 H.C. Wainwright
Dentsply Sirona price target lowered to $66 from $72 at H.C. Wainwright
08/06/21 Barrington
Dentsply Sirona price target raised to $79 from $77 at Barrington
08/06/21 Piper Sandler
Dentsply Sirona weakness a buying opportunity, says Piper Sandler
VIR Vir Biotechnology
$51.51 /

+1.51 (+3.02%)

06/03/21 Baird
Vir Biotechnology assumed with a Neutral at Baird
05/27/21 Piper Sandler
Xencorc royalty revenue streams growing, says Piper Sandler
03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
03/08/21 H.C. Wainwright
Vir Biotechnology price target raised to $135 from $125 at H.C. Wainwright
TNDM TNDM
/

+

08/05/21 SVB Leerink
Tandem Diabetes price target raised to $123 from $102 at SVB Leerink
08/05/21 Craig-Hallum
Tandem Diabetes price target raised to $153 from $140 at Craig-Hallum
08/05/21 Wells Fargo
Tandem Diabetes price target raised to $121 from $112 at Wells Fargo
08/05/21 Oppenheimer
Tandem Diabetes price target raised to $140 from $135 at Oppenheimer
TLMD SOC Telemed
$2.97 /

+0.065 (+2.24%)

09/01/21 Benchmark
SOC Telemed CEO change due to 'uneven' performance, says Benchmark
08/13/21 RBC Capital
SOC Telemed price target lowered to $6 from $10 at RBC Capital
08/13/21 Benchmark
SOC Telemed price target lowered to $7 from $10 at Benchmark
05/28/21 Baird
Baird starts 'uniquely well-positioned' SOC Telemed with an Outperform
TRHC Tabula Rasa HealthCare
$29.76 /

+0.02 (+0.07%)

06/03/21 Truist
Tabula Rasa HealthCare price target raised to $47 from $42 at Truist
05/28/21 Baird
Baird starts Tabula Rasa HealthCare with Outperform amid low expectations
05/27/21 Baird
Tabula Rasa HealthCare initiated with an Outperform at Baird
05/07/21 Piper Sandler
Tabula Rasa price target raised to $45 from $41 at Piper Sandler
ZBH Zimmer Biomet
$140.76 /

-0.18 (-0.13%)

09/14/21 Raymond James
Zimmer Biomet resumed with a Market Perform at Raymond James
08/30/21 Cowen
Zimmer Biomet approval 'kicks off' smart implant era in orthopedics, says Cowen
08/30/21 Piper Sandler
Piper says Persona IQ represents 'another exciting approval' for Zimmer Biomet
08/25/21 Citi
Citi adds Medtronic to Focus List, boosts price target
MRVL Marvell
$62.64 /

+0.25 (+0.40%)

08/27/21
Fly Intel: Top five analyst downgrades
08/27/21 Craig-Hallum
Marvell downgraded to Hold on valuation at Craig-Hallum
08/27/21 Craig-Hallum
Marvell downgraded to Hold from Buy at Craig-Hallum
08/27/21 B. Riley
Marvell earnings selloff brings 'enhanced entry point,' says B. Riley
TIL Instil Bio
$18.57 /

+0.84 (+4.74%)

08/13/21 Baird
Baird sees likely success for Instil Bio lead candidate, starts at Outperform
08/12/21 Baird
Instil Bio initiated with an Outperform at Baird
06/29/21 Chardan
Iovance data show activity but 'not a home run,' says Chardan
05/19/21 Chardan
Iovance Biotherapeutics price target lowered to $51 from $54 at Chardan
TECH Bio-Techne
$510.21 /

+7.82 (+1.56%)

08/24/21 Argus
Bio-Techne price target raised to $540 from $490 at Argus
08/06/21 Baird
Bio-Techne price target raised to $522 from $430 at Baird
08/05/21 Benchmark
Bio-Techne price target raised to $540 from $480 at Benchmark
06/18/21 Argus
Bio-Techne price target raised to $490 from $440 at Argus
TALK Talkspace
$4.84 /

-0.015 (-0.31%)

08/19/21 Citi
Talkspace initiated with a Buy at Citi
07/19/21 William Blair
Talkspace initiated with an Outperform at William Blair
07/08/21 Baird
Talkspace initiated with an Outperform at Baird
07/06/21 Cowen
Talkspace initiated with an Outperform at Cowen
ZBH Zimmer Biomet
$140.76 /

-0.18 (-0.13%)

XRAY Dentsply Sirona
$62.66 /

+0.82 (+1.33%)

VIR Vir Biotechnology
$51.51 /

+1.51 (+3.02%)

TRHC Tabula Rasa HealthCare
$29.76 /

+0.02 (+0.07%)

TNDM TNDM
/

+

TLMD SOC Telemed
$2.97 /

+0.065 (+2.24%)

TIL Instil Bio
$18.57 /

+0.84 (+4.74%)

TALK Talkspace
$4.84 /

-0.015 (-0.31%)

STE Steris
$211.52 /

+1.16 (+0.55%)

SRPT Sarepta
$81.79 /

-0.07 (-0.09%)

RCM R1 RCM
$20.47 /

+0.06 (+0.29%)

NTRA Natera
$122.38 /

+2.15 (+1.79%)

NOVT Novanta
$151.80 /

-0.545 (-0.36%)

MYOV Myovant Sciences
$22.85 /

+0.07 (+0.31%)

MRVL Marvell
$62.64 /

+0.25 (+0.40%)

JNCE Jounce Therapeutics
$7.23 /

+0.755 (+11.66%)

IVC Invacare
$6.95 /

+0.42 (+6.43%)

IQV Iqvia
$258.35 /

+2.73 (+1.07%)

ICPT Intercept
$14.66 /

-0.125 (-0.85%)

HGEN Humanigen
$6.35 /

+0.11 (+1.76%)

GERN Geron
$1.38 /

-0.01 (-0.72%)

FATE Fate Therapeutics
$66.74 /

+0.93 (+1.41%)

COO Cooper Companies
$442.66 /

+2.08 (+0.47%)

ASMB Assembly Biosciences
$3.30 /

-0.01 (-0.30%)

AHCO AdaptHealth
$24.25 /

+0.36 (+1.51%)

ABUS Arbutus Biopharma
$4.22 /

-0.035 (-0.82%)

  • 22
    Jul
  • 27
    May
  • 27
    May
  • 31
    Mar
  • 19
    Mar
  • 10
    Mar
  • 06
    Jan
  • 06
    Jan
  • 15
    Dec
  • 18
    Sep
XRAY Dentsply Sirona
$62.66 /

+0.82 (+1.33%)

SRPT Sarepta
$81.79 /

-0.07 (-0.09%)

MRVL Marvell
$62.64 /

+0.25 (+0.40%)

ZBH Zimmer Biomet
$140.76 /

-0.18 (-0.13%)

VIR Vir Biotechnology
$51.51 /

+1.51 (+3.02%)

TLMD SOC Telemed
$2.97 /

+0.065 (+2.24%)

TIL Instil Bio
$18.57 /

+0.84 (+4.74%)

STE Steris
$211.52 /

+1.16 (+0.55%)

SRPT Sarepta
$81.79 /

-0.07 (-0.09%)

RCM R1 RCM
$20.47 /

+0.06 (+0.29%)

NTRA Natera
$122.38 /

+2.15 (+1.79%)

MYOV Myovant Sciences
$22.85 /

+0.07 (+0.31%)

MRVL Marvell
$62.64 /

+0.25 (+0.40%)

IVC Invacare
$6.95 /

+0.42 (+6.43%)

ICPT Intercept
$14.66 /

-0.125 (-0.85%)

HGEN Humanigen
$6.35 /

+0.11 (+1.76%)

GERN Geron
$1.38 /

-0.01 (-0.72%)

FATE Fate Therapeutics
$66.74 /

+0.93 (+1.41%)

AHCO AdaptHealth
$24.25 /

+0.36 (+1.51%)

ABUS Arbutus Biopharma
$4.22 /

-0.035 (-0.82%)

TALK Talkspace
$4.84 /

-0.015 (-0.31%)

STE Steris
$211.52 /

+1.16 (+0.55%)

MRVL Marvell
$62.64 /

+0.25 (+0.40%)

HGEN Humanigen
$6.35 /

+0.11 (+1.76%)

GERN Geron
$1.38 /

-0.01 (-0.72%)

COO Cooper Companies
$442.66 /

+2.08 (+0.47%)

ABUS Arbutus Biopharma
$4.22 /

-0.035 (-0.82%)

Over a week ago
Hot Stocks
Vir Biotechnology announces first marketing authorization for sotrovimab » 08:38
08/23/21
08/23
08:38
08/23/21
08:38
VIR

Vir Biotechnology

$46.40 /

+1.29 (+2.86%)

, GSK

GlaxoSmithKline

$41.85 /

+0.04 (+0.10%)

Vir Biotechnology (VIR)…

Vir Biotechnology (VIR) announced the first marketing authorization, granted in Australia, for its first commercial product, sotrovimab, developed in partnership with GlaxoSmithKline (GSK). This announcement follows news shared by GSK Australia that the Australian Therapeutic Goods Administration has granted provisional marketing authorization for sotrovimab, a monoclonal antibody for the treatment of adults and adolescents with COVID-19 who do not require initiation of oxygen due to COVID-19 and who are at increased risk of progression to hospitalization or death. Sotrovimab is the first monoclonal antibody approved in Australia. As part of its overarching effort to address COVID-19, the Australian Government also recently announced an agreement to purchase sotrovimab, the first supply of which arrived in the country last week. Globally, sotrovimab is authorized for emergency use in the U.S., received a positive scientific opinion from the Committee for Human Medicinal Products in the European Union, and has been granted temporary authorization in Bahrain, Canada, Egypt, Italy, Kuwait, Qatar, Singapore and the United Arab Emirates. George Scangos, Ph.D., chief executive officer of Vir, said: "The provisional approval of sotrovimab in Australia marks an important milestone for Vir, as it is the first marketing authorization of our first commercial product. It also represents an important step forward in the Australian Government's efforts to combat the pandemic and prevent the most severe effects of COVID-19, particularly in the face of new and emerging variants. We eagerly anticipate additional regulatory decisions around the world in the coming months and look forward to working with our partner, GSK, to expand patient access to a much-needed treatment option that continues to demonstrate, in vitro, its ability to retain activity against the tested, currently circulating variants of concern and interest, including Delta and Delta Plus."

ShowHide Related Items >><<
VIR Vir Biotechnology
$46.40 /

+1.29 (+2.86%)

GSK GlaxoSmithKline
$41.85 /

+0.04 (+0.10%)

VIR Vir Biotechnology
$46.40 /

+1.29 (+2.86%)

06/03/21 Baird
Vir Biotechnology assumed with a Neutral at Baird
05/27/21 Piper Sandler
Xencorc royalty revenue streams growing, says Piper Sandler
03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
03/08/21 H.C. Wainwright
Vir Biotechnology price target raised to $135 from $125 at H.C. Wainwright
GSK GlaxoSmithKline
$41.85 /

+0.04 (+0.10%)

08/20/21 JPMorgan
GlaxoSmithKline price target raised to 1,500 GBp from 1,300 GBp at JPMorgan
08/19/21 Berenberg
GlaxoSmithKline price target raised to 1,625 GBp from 1,570 GBp at Berenberg
08/18/21 Wedbush
AnaptysBio price target raised to $25 from $20 at Wedbush
08/03/21 UBS
GlaxoSmithKline price target lowered to 1,485 GBp from 1,500 GBp at UBS
VIR Vir Biotechnology
$46.40 /

+1.29 (+2.86%)

GSK GlaxoSmithKline
$41.85 /

+0.04 (+0.10%)

GSK GlaxoSmithKline
$41.85 /

+0.04 (+0.10%)

VIR Vir Biotechnology
$46.40 /

+1.29 (+2.86%)

GSK GlaxoSmithKline
$41.85 /

+0.04 (+0.10%)

GSK GlaxoSmithKline
$41.85 /

+0.04 (+0.10%)

Over a month ago
Earnings
Vir Biotechnology reports Q2 EPS 46c, consensus (48c) » 17:16
08/05/21
08/05
17:16
08/05/21
17:16
VIR

Vir Biotechnology

$37.64 /

+0.385 (+1.03%)

Reports Q2 revenue…

Reports Q2 revenue $177.07M, consensus $84.56M. Contract revenue for the quarter ended June 30 was $168.7M, compared to $43.5M for the same period in 2020. The increase for the quarter was primarily due to $168.3M from deferred revenue related to the license granted to GSK under the company's 2021 GSK agreement. "Vir made strong progress this quarter across our extensive infectious disease portfolio, the most notable of which is that our monoclonal antibody sotrovimab is now available for patients who become ill with COVID-19 and are at high risk for hospitalization," said George Scangos, chief executive officer of Vir Biotechnology. "In lab experiments, sotrovimab retains efficacy against circulating variants of concern and interest, including the Delta, Delta Plus and Lambda variants. Additionally, its low dose may allow for more convenient intramuscular administration, which is now being tested in two clinical trials. Sotrovimab has been authorized for emergency use and, with our partner GSK, we have established supply agreements with multiple countries around the world. Together, we plan to submit a Biologics License Application to the FDA later this year and, in May of this year, the EMA began a rolling review of data to support a marketing authorization application in Europe."

ShowHide Related Items >><<
VIR Vir Biotechnology
$37.64 /

+0.385 (+1.03%)

VIR Vir Biotechnology
$37.64 /

+0.385 (+1.03%)

06/03/21 Baird
Vir Biotechnology assumed with a Neutral at Baird
05/27/21 Piper Sandler
Xencorc royalty revenue streams growing, says Piper Sandler
03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
03/08/21 H.C. Wainwright
Vir Biotechnology price target raised to $135 from $125 at H.C. Wainwright
VIR Vir Biotechnology
$37.64 /

+0.385 (+1.03%)

Hot Stocks
GSK Covid injection granted Interim Order authorization in Canada » 14:43
07/30/21
07/30
14:43
07/30/21
14:43
GSK

GlaxoSmithKline

$40.06 /

-0.04 (-0.10%)

, VIR

Vir Biotechnology

$35.36 /

-1.33 (-3.62%)

GlaxoSmithKline (GSK)…

GlaxoSmithKline (GSK) announced that Health Canada has granted an Interim Order authorization for Sotrovimab for Injection for the treatment of mild to moderate COVID-19, confirmed by direct SARS-COV-2 viral testing, in adults and adolescents who are at high risk for progressing to hospitalization and/or death. The authorization of sotrovimab, a single-dose monoclonal antibody developed in collaboration with Vir Biotechnology (VIR), was granted under Health Canada's Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. Health Canada's Interim Order expedites authorization of medicines used for COVID-19, considering public health need.

ShowHide Related Items >><<
VIR Vir Biotechnology
$35.36 /

-1.33 (-3.62%)

GSK GlaxoSmithKline
$40.06 /

-0.04 (-0.10%)

GSK GlaxoSmithKline
$40.06 /

-0.04 (-0.10%)

07/19/21 Barclays
GlaxoSmithKline price target raised to 1,300 GBp from 1,250 GBp at Barclays
07/06/21 Morgan Stanley
GlaxoSmithKline price target raised to 1,590 GBp at Morgan Stanley
07/06/21 Citi
Alector price target raised to $43 from $31 at Citi
07/02/21 Goldman Sachs
GSK collaboration 'positive' for Alector, says Goldman Sachs
VIR Vir Biotechnology
$35.36 /

-1.33 (-3.62%)

06/03/21 Baird
Vir Biotechnology assumed with a Neutral at Baird
05/27/21 Piper Sandler
Xencorc royalty revenue streams growing, says Piper Sandler
03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
03/08/21 H.C. Wainwright
Vir Biotechnology price target raised to $135 from $125 at H.C. Wainwright
GSK GlaxoSmithKline
$40.06 /

-0.04 (-0.10%)

GSK GlaxoSmithKline
$40.06 /

-0.04 (-0.10%)

VIR Vir Biotechnology
$35.36 /

-1.33 (-3.62%)

GSK GlaxoSmithKline
$40.06 /

-0.04 (-0.10%)

GSK GlaxoSmithKline
$40.06 /

-0.04 (-0.10%)

Hot Stocks
GSK, Vir Biotechnology announce joint procurement pact with EC for sotrovimab » 06:22
07/28/21
07/28
06:22
07/28/21
06:22
GSK

GlaxoSmithKline

$39.52 /

+0.495 (+1.27%)

, VIR

Vir Biotechnology

$36.41 /

-0.54 (-1.46%)

GlaxoSmithKline (GSK) and…

GlaxoSmithKline (GSK) and Vir Biotechnology (VIR) announced they have signed a Joint Procurement Agreement with the European Commission to supply up to 220,000 doses of sotrovimab, an investigational single dose SARS-CoV-2 monoclonal antibody for the treatment of adults and adolescents with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19. The Joint Procurement Agreement enables participating European Union Member States to quickly purchase sotrovimab, following local emergency authorization or authorization at the EU level, to treat high-risk patients with COVID-19 who may benefit from early treatment with sotrovimab.

ShowHide Related Items >><<
VIR Vir Biotechnology
$36.41 /

-0.54 (-1.46%)

GSK GlaxoSmithKline
$39.52 /

+0.495 (+1.27%)

GSK GlaxoSmithKline
$39.52 /

+0.495 (+1.27%)

07/19/21 Barclays
GlaxoSmithKline price target raised to 1,300 GBp from 1,250 GBp at Barclays
07/06/21 Morgan Stanley
GlaxoSmithKline price target raised to 1,590 GBp at Morgan Stanley
07/06/21 Citi
Alector price target raised to $43 from $31 at Citi
07/02/21 Goldman Sachs
GSK collaboration 'positive' for Alector, says Goldman Sachs
VIR Vir Biotechnology
$36.41 /

-0.54 (-1.46%)

06/03/21 Baird
Vir Biotechnology assumed with a Neutral at Baird
05/27/21 Piper Sandler
Xencorc royalty revenue streams growing, says Piper Sandler
03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
03/08/21 H.C. Wainwright
Vir Biotechnology price target raised to $135 from $125 at H.C. Wainwright
GSK GlaxoSmithKline
$39.52 /

+0.495 (+1.27%)

GSK GlaxoSmithKline
$39.52 /

+0.495 (+1.27%)

VIR Vir Biotechnology
$36.41 /

-0.54 (-1.46%)

GSK GlaxoSmithKline
$39.52 /

+0.495 (+1.27%)

GSK GlaxoSmithKline
$39.52 /

+0.495 (+1.27%)

Hot Stocks
Vir Biotechnology initiates Phase 2 clinical trial evaluating VIR-2218, VIR-3434 » 08:33
07/15/21
07/15
08:33
07/15/21
08:33
VIR

Vir Biotechnology

$35.44 /

-0.79 (-2.18%)

Vir Biotechnology…

Vir Biotechnology announced that the first patient has been dosed in the Phase 2 MARCH trial evaluating VIR-2218 together with VIR-3434 for the treatment of patients with chronic hepatitis B virus infection - a combination designed to achieve a functional cure.VIR-2218 is an investigational small interfering ribonucleic acid designed to inhibit the production of all HBV proteins, which may be acting as immune tolerogens. The multi-center, open-label Phase 2 trial is designed to evaluate the safety, tolerability and efficacy of the combination of VIR-2218 and VIR-3434 in approximately 90 adult patients with chronic HBV infection receiving nucleotside reverse transcriptase inhibitor therapy. Both VIR-2218 and VIR-3434 will be administered via subcutaneous injection at varying dose levels over the course of the trial for a treatment period ranging from four to 20 weeks, and a follow-up period of up to 116 weeks, depending on the dosing cohort. The primary endpoints of the trial are the proportion of patients with treatment-emergent adverse events and serious adverse events; grading of post-treatment clinical laboratory parameters; and the proportion of patients achieving a functional cure.

ShowHide Related Items >><<
VIR Vir Biotechnology
$35.44 /

-0.79 (-2.18%)

VIR Vir Biotechnology
$35.44 /

-0.79 (-2.18%)

06/03/21 Baird
Vir Biotechnology assumed with a Neutral at Baird
05/27/21 Piper Sandler
Xencorc royalty revenue streams growing, says Piper Sandler
03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
03/08/21 H.C. Wainwright
Vir Biotechnology price target raised to $135 from $125 at H.C. Wainwright
VIR Vir Biotechnology
$35.44 /

-0.79 (-2.18%)

Hot Stocks
GSK, Vir Biotechnology announce advance purchase agreement with Singapore » 09:32
06/30/21
06/30
09:32
06/30/21
09:32
GSK

GlaxoSmithKline

$39.98 /

+0.085 (+0.21%)

, VIR

Vir Biotechnology

$46.55 /

-0.39 (-0.83%)

GlaxoSmithKline (GSK)…

GlaxoSmithKline (GSK) Singapore and Vir Biotechnology (VIR) announced an agreement with the Government of Singapore for the supply of sotrovimab, an investigational single-dose monoclonal antibody, for the treatment of patients with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19. GSK Singapore has submitted an application under the Pandemic Special Access Route, or PSAR, for sotrovimab to the Health Sciences Authority of Singapore. Sotrovimab is currently undergoing regulatory review for interim authorization under the PSAR. GSK and Vir are in discussions with other governments to explore similar supply agreements, as countries accelerate their vaccine and therapeutics programmes against COVID-19.

ShowHide Related Items >><<
VIR Vir Biotechnology
$46.55 /

-0.39 (-0.83%)

GSK GlaxoSmithKline
$39.98 /

+0.085 (+0.21%)

GSK GlaxoSmithKline
$39.98 /

+0.085 (+0.21%)

06/24/21 Credit Suisse
GlaxoSmithKline price target raised to 1,400 GBp at Credit Suisse
06/24/21 Deutsche Bank
Deutsche Bank upgrades GSK to Hold on 'obviously improving' story
06/23/21 Deutsche Bank
GlaxoSmithKline upgraded to Hold from Sell at Deutsche Bank
06/14/21 Piper Sandler
iTeos deal 'addresses a number of needs all at once, says Piper Sandler
VIR Vir Biotechnology
$46.55 /

-0.39 (-0.83%)

06/03/21 Baird
Vir Biotechnology assumed with a Neutral at Baird
05/27/21 Piper Sandler
Xencorc royalty revenue streams growing, says Piper Sandler
03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
03/08/21 H.C. Wainwright
Vir Biotechnology price target raised to $135 from $125 at H.C. Wainwright
GSK GlaxoSmithKline
$39.98 /

+0.085 (+0.21%)

  • 08
    Jul
GSK GlaxoSmithKline
$39.98 /

+0.085 (+0.21%)

VIR Vir Biotechnology
$46.55 /

-0.39 (-0.83%)

GSK GlaxoSmithKline
$39.98 /

+0.085 (+0.21%)

GSK GlaxoSmithKline
$39.98 /

+0.085 (+0.21%)

Hot Stocks
Vir Biotechnology presents clinical data from trials of VIR-2218, VIR-3434 » 08:53
06/25/21
06/25
08:53
06/25/21
08:53
VIR

Vir Biotechnology

$49.52 /

+2.45 (+5.21%)

Vir Biotechnology…

Vir Biotechnology announced new data from its ongoing Phase 2 clinical trials of VIR-2218 and ongoing Phase 1 studies of VIR-3434 in patients with chronic hepatitis B virus infection. The results, which demonstrate positive safety findings plus a reduction in hepatitis B surface antigen for both compounds, were presented in two oral and two poster presentations at the European Association for the Study of the Liver International Liver Congress 2021, which is taking place virtually. Vir will hold a conference call and webcast, Friday, June 25, 2021, at 11:00 a.m. ET, to discuss the new data presented at the meeting. In summary, data presented this week demonstrate the promising safety profile and potential durable response of VIR-2218, an investigational small interfering ribonucleic acid that mediates RNA interference, through 48 weeks. In a separate analysis evaluating VIR-2218 in combination with pegylated interferon alfa for 12 weeks, a more rapid and substantial HBsAg decline was observed in the co-administration cohort compared to VIR-2218 alone. The treatment regimen resulted in no new safety signals. Additionally, two new analyses from an ongoing Phase 1 trial of VIR-3434 showed no safety signals in healthy volunteers dosed with up to 3,000 mg, and a rapid reduction in HBsAg levels one week after subcutaneous administration of this investigational HBV-neutralizing monoclonal antibody, which has been Fc engineered to include the XX2 "vaccinal mutation," allowing it to potentially function as a T cell vaccine. VIR-2218: Key Data: Results from a Phase 2 multiple-ascending dose trial of VIR-2218 in 32 patients with chronic HBV infection evaluating the safety and antiviral activity of two doses of VIR-2218 administered subcutaneously four weeks apart demonstrate: Dose-dependent reductions in HBsAg through 48 weeks in both trial participants with hepatitis B e antigen, a marker of actively replicating HBV, and those without. Of the 12 participants who received the 100 mg or 200 mg dose, four participants experienced sustained HBsAg reductions of greater than1 log10 IU/mL and absolute HBsAg levels below 100 IU/mL through Week 48. Treatment with VIR-2218 achieved dose-related reductions in other viral biomarkers; one patient receiving 200 mg experienced HBeAg loss at Week 24 and anti-HBe seroconversion at Week 16 that was sustained through Week 48. Adverse events were mild, and no dose-dependent changes in post-treatment ALT levels occurred. No trial participants discontinued treatment. In a separate ongoing Phase 2 trial, 47 adult patients with chronic HBV infection were assigned to receive subcutaneously injected VIR-2218 alone or in combination with PEG-IFN-alpha. Preliminary results through Week 12 of the treatment period demonstrate: VIR-2218 alone and in combination with PEG-IFN-alpha were associated with HBsAg reductions of greater than1 log10 IU/mL by Week 12. Co-administration of VIR-2218 with PEG-IFN-alpha resulted in a more rapid and substantial HBsAg decline compared to VIR-2218 alone. In Cohort 3, the mean HBsAg decline from baseline was 2.0 log10 IU/mL at Week 12 and 0.6 log10 IU/mL greater than in the two cohorts evaluating VIR-2218 alone. In published studies, PEG-IFN-alpha alone in virally suppressed patients was associated with less than or equal to 0.25 log10 IU/mL HBsAg decline, on average, over the first 12 weeks. No treatment-related grade greater than or equal to3 treatment-emergent adverse events or serious adverse events were reported with VIR-2218 alone or in combination with PEG-IFN-alpha, and the combination did not appear to increase the known side effects of PEG-IFN-alpha. VIR-3434: Key Data: Results from a Phase 1 trial evaluating VIR-3434 in 40 virally suppressed patients with chronic HBV infection who were randomized to receive a single low dose of either 6 mg or 18 mg for four weeks demonstrate: Treatment with VIR-3434 resulted in rapid greater than1 log10 IU/mL reductions in HBsAg, with the largest reductions observed in the 18 mg cohort; maximum reductions were generally observed within one week. No new safety signals were identified with single doses of VIR-3434; all adverse events were grade 1 or 2. No significant changes in liver-related laboratory parameters or clinically significant changes in ALT or other liver-related laboratory parameters were reported. In a separate Phase 1 trial in 40 healthy adult volunteers evaluating single doses of up to 3,000 mg of VIR-3434 administered subcutaneously or intravenously, results demonstrate: Subcutaneous administration of VIR-3434 showed favorable pharmacokinetic properties, with VIR-3434 remaining in the serum for 24 weeks. No new safety signals were identified; specifically, no grade 3/4 adverse events, serious adverse events or adverse events leading to trial discontinuation were reported.

ShowHide Related Items >><<
VIR Vir Biotechnology
$49.52 /

+2.45 (+5.21%)

VIR Vir Biotechnology
$49.52 /

+2.45 (+5.21%)

06/03/21 Baird
Vir Biotechnology assumed with a Neutral at Baird
05/27/21 Piper Sandler
Xencorc royalty revenue streams growing, says Piper Sandler
03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
03/08/21 H.C. Wainwright
Vir Biotechnology price target raised to $135 from $125 at H.C. Wainwright
  • 08
    Jul
VIR Vir Biotechnology
$49.52 /

+2.45 (+5.21%)

Conference/Events
Vir Biotechnology to host conference call » 10:45
06/22/21
06/22
10:45
06/22/21
10:45
VIR

Vir Biotechnology

$49.64 /

+0.54 (+1.10%)

Management discusses the…

Management discusses the new data on Hepatitis B being presented at the European Association for the Study of the Liver (EASL) Digital International Liver Congress on a conference call to be held on June 25 at 11 am. Webcast Link

ShowHide Related Items >><<
VIR Vir Biotechnology
$49.64 /

+0.54 (+1.10%)

VIR Vir Biotechnology
$49.64 /

+0.54 (+1.10%)

06/03/21 Baird
Vir Biotechnology assumed with a Neutral at Baird
05/27/21 Piper Sandler
Xencorc royalty revenue streams growing, says Piper Sandler
03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
03/08/21 H.C. Wainwright
Vir Biotechnology price target raised to $135 from $125 at H.C. Wainwright
  • 08
    Jul
VIR Vir Biotechnology
$49.64 /

+0.54 (+1.10%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.